Toxoplasma gondii infection as a potential risk for chronic liver diseases: A systematic review and meta-analysis.


Journal

Microbial pathogenesis
ISSN: 1096-1208
Titre abrégé: Microb Pathog
Pays: England
ID NLM: 8606191

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 01 09 2020
revised: 09 10 2020
accepted: 12 10 2020
pubmed: 19 10 2020
medline: 22 6 2021
entrez: 18 10 2020
Statut: ppublish

Résumé

Toxoplasma gondii, the etiological agent of toxoplasmosis, can cause serious public health problems. Although Toxoplasma gondii tends more to neurotropic and ocular organs, some existing evidence suggest that this disease might induce serious pathological effects on liver. Hence, this study aimed to evaluate the relationship between chronic liver diseases and toxoplasmosis. Meanwhile, it attempted to assess whether patients with toxoplasmosis are susceptible to chronic liver diseases. To achieve this aim, the published studies related to the subject were systematically searched in five major electronic databases between the January 1, 1950 and October 1, 2019. The meta-analysis was carried out using the StatsDirect statistical software and a p-value less than 0.05 was considered significant for any test. Out of 691 identified studies, 10 studies met our inclusion criteria and entered this systematic review. The pooled prevalence rates of Toxoplasma gondii in patients with liver diseases (35.97%; 95% CI: 28.38-43.93) were higher than those in the control group (18.24%; 95% CI: 13.85-23.09). The meta-analysis indicated that the common Odd Ratio by a random effect model was 2.7 (95% CI: 2.30-3.24), revealing a significant association between chronic liver diseases and anti-Toxoplasma IgG antibody. The results of this systematic review confirmed the positive connection between toxoplasmosis and chronic liver diseases. Nonetheless, more studies are needed to clarify the detailed association between these diseases.

Identifiants

pubmed: 33069795
pii: S0882-4010(20)30944-X
doi: 10.1016/j.micpath.2020.104578
pii:
doi:

Substances chimiques

Antibodies, Protozoan 0

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104578

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Hossein Pazoki (H)

Student Research Committee, Department of Medical Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Medical Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Masood Ziaee (M)

Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.

Davood Anvari (D)

Student Research Committee, Mazandaran University of Medical Science, Sari, Iran; School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran.

Fatemeh Rezaei (F)

Islamic Azad University of Chalus Branch, Chalus, Iran.

Ehsan Ahmadpour (E)

Department of Parasitology and Mycology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Beheshteh Haghparast-Kenari (B)

Student Research Committee, Mazandaran University of Medical Science, Sari, Iran.

Fatemeh Saljoghi (F)

Department of Radiology, Ali Ebne Abitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran.

Farid Tahvildar Biderouni (FT)

Department of Medical Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Aleksandra Barac (A)

Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, 11000, Belgrade, Serbia.

Abdol Sattar Pagheh (AS)

Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran. Electronic address: satar2011@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH